130 related articles for article (PubMed ID: 32030755)
1. Cell-based, animal and H
Feng F; Fawcett JP; Zhang H; Tucker IG
J Pharm Pharmacol; 2020 Apr; 72(4):507-518. PubMed ID: 32030755
[TBL] [Abstract][Full Text] [Related]
2. Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization.
Hishinuma S; Sato Y; Kobayashi Y; Komazaki H; Saito M
J Pharmacol Sci; 2008 May; 107(1):66-79. PubMed ID: 18446005
[TBL] [Abstract][Full Text] [Related]
3. Quantitative prediction of histamine H1 receptor occupancy by the sedative and non-sedative antagonists in the human central nervous system based on systemic exposure and preclinical data.
Kanamitsu K; Nozaki Y; Nagaya Y; Sugiyama Y; Kusuhara H
Drug Metab Pharmacokinet; 2017 Apr; 32(2):135-144. PubMed ID: 28190755
[TBL] [Abstract][Full Text] [Related]
4. Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier.
Ishiguro N; Nozawa T; Tsujihata A; Saito A; Kishimoto W; Yokoyama K; Yotsumoto T; Sakai K; Igarashi T; Tamai I
Drug Metab Dispos; 2004 May; 32(5):519-24. PubMed ID: 15100174
[TBL] [Abstract][Full Text] [Related]
5. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies.
Sharif NA; Su SX; Yanni JM
J Ocul Pharmacol; 1994; 10(4):653-64. PubMed ID: 7714409
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characteristics of Sho-seiryu-to, an antiallergic Kampo medicine without effects on histamine H1 receptors and muscarinic cholinergic system in the brain.
Sakaguchi M; Iizuka A; Yuzurihara M; Ishige A; Komatsu Y; Matsumiya T; Takeda H
Methods Find Exp Clin Pharmacol; 1996; 18(1):41-7. PubMed ID: 8721255
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
Sharif NA; Xu SX; Miller ST; Gamache DA; Yanni JM
J Pharmacol Exp Ther; 1996 Sep; 278(3):1252-61. PubMed ID: 8819509
[TBL] [Abstract][Full Text] [Related]
8. Relationship between occupation of cerebral H1-receptors and sedative properties of antihistamines. Assessment in the case of terfenadine.
Rose C; Quach TT; Llorens C; Schwartz JC
Arzneimittelforschung; 1982; 32(9a):1171-3. PubMed ID: 6129863
[TBL] [Abstract][Full Text] [Related]
9. Studies on the novel antiallergic agent HSR-609: its penetration into the central nervous system in mice and guinea pigs and its selectivity for the histamine H1-receptor.
Kakiuchi M; Ohashi T; Musoh K; Kawamura K; Morikawa K; Kato H
Jpn J Pharmacol; 1997 Apr; 73(4):291-8. PubMed ID: 9165365
[TBL] [Abstract][Full Text] [Related]
10. Ketotifen is a Prodrug. Norketotifen is the active metabolite.
Aberg AKG; Arulnesan N; Bolger GT; Ciofalo VB; Pucaj K; Walle K; Walle T
Drug Dev Res; 2022 Apr; 83(2):362-367. PubMed ID: 34410005
[TBL] [Abstract][Full Text] [Related]
11. Histamine H1 receptor and reactivity of the nasal mucosa in sensitized guinea pigs.
Ohkawa C; Ukai K; Miyahara Y; Takeuchi K; Sakakura Y
Auris Nasus Larynx; 1999 Jul; 26(3):293-8. PubMed ID: 10419037
[TBL] [Abstract][Full Text] [Related]
12. Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen.
Tashiro M; Mochizuki H; Sakurada Y; Ishii K; Oda K; Kimura Y; Sasaki T; Ishiwata K; Yanai K
Br J Clin Pharmacol; 2006 Jan; 61(1):16-26. PubMed ID: 16390347
[TBL] [Abstract][Full Text] [Related]
13. Characterization of histamine H1-receptors on astrocytes in primary culture: [3H]mepyramine binding studies.
Inagaki N; Fukui H; Taguchi Y; Wang NP; Yamatodani A; Wada H
Eur J Pharmacol; 1989 Nov; 173(1):43-51. PubMed ID: 2575040
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of the binding of [3H]-mepyramine to intact human U373 MG astrocytoma cells: evidence for histamine-induced H1-receptor internalisation.
Hishinuma S; Young JM
Br J Pharmacol; 1995 Nov; 116(6):2715-23. PubMed ID: 8590995
[TBL] [Abstract][Full Text] [Related]
15. Effects of second-generation histamine H1 receptor antagonists on the sleep-wakefulness cycle in rats.
Shigemoto Y; Shinomiya K; Mio M; Azuma N; Kamei C
Eur J Pharmacol; 2004 Jun; 494(2-3):161-5. PubMed ID: 15212970
[TBL] [Abstract][Full Text] [Related]
16. Preclinical comparison of ebastine and other second generation H1-antihistamines.
Yakuo I; Yabuuchi M; Ito T
Pharmacol Toxicol; 2001 Oct; 89(4):171-6. PubMed ID: 11881966
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography evaluation of sedative properties of antihistamines.
Yanai K; Zhang D; Tashiro M; Yoshikawa T; Naganuma F; Harada R; Nakamura T; Shibuya K; Okamura N
Expert Opin Drug Saf; 2011 Jul; 10(4):613-22. PubMed ID: 21521134
[TBL] [Abstract][Full Text] [Related]
18. Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites.
Hals PA; Hall H; Dahl SG
Life Sci; 1988; 43(5):405-12. PubMed ID: 2899826
[TBL] [Abstract][Full Text] [Related]
19. Affinities of histamine H1-antagonists in guinea pig brain: similarity of values determined from [3H]mepyramine binding and from inhibition of a functional response.
Hill SJ; Daum P; Young JM
J Neurochem; 1981 Nov; 37(5):1357-60. PubMed ID: 6117608
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants responsible for sedative and non-sedative properties of histamine H₁-receptor antagonists.
Uesawa Y; Hishinuma S; Shoji M
J Pharmacol Sci; 2014; 124(2):160-8. PubMed ID: 24476926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
